Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment

• Published in: Internal Medicine Vol. 57; no. 9; pp. 1219 - 1227
• Main Authors: Ikegami, Tadashi, Honda, Akira, Kohjima, Motoyuki, Miyazaki, Teruo, Yara, Sho-Ichiro, Matsuzaki, Yasushi, Nakamuta, Makoto, Hirayama, Takeshi
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Internal Medicine 01.05.2018
• Subjects: 4β-hydroxycholesterol; Aged; Anilides - therapeutic use; Antiviral Agents - therapeutic use; Carbamates - therapeutic use; Case-Control Studies; Cytochrome P-450 CYP3A - metabolism; cytochrome P450 (CYP) 3A4; direct acting antivirals; Drug Therapy, Combination; Female; Genotype; HCV; Hepatitis C - drug therapy; Hepatitis C, Chronic - drug therapy; Humans; Hydroxycholesterols - blood; Imidazoles - therapeutic use; Interferons - administration & dosage; Interferons - adverse effects; Interferons - therapeutic use; Isoquinolines - therapeutic use; Macrocyclic Compounds - therapeutic use; Male; Middle Aged; Original; oxysterol; Ritonavir - therapeutic use; Sex Factors; Sulfonamides - therapeutic use; Treatment Failure; oxysterol; HCV; 4β-hydroxycholesterol; direct acting antivirals; cytochrome P450 (CYP) 3A4

Objective Since the majority of direct-acting antivirals (DAAs) that are used in the treatment of hepatitis C virus (HCV) infection are mainly metabolized by CYP3A4, it is hypothesized that inter-individual differences in CYP3A4 activity may be associated with the bioavailability of these agents. Me...